Endoscopic polyp measurements
| Placebo | EPA-FFA | |||||
| BL | 6 m | Δ (6 months–BL) | BL | 6 m | Δ (6 months–BL) | |
| (95% CI) | (95% CI) | |||||
| No. polyps* (mean±SD) | 4.50±2.63 | 5.05±3.30 | 0.54 (0.03 to 1.05) | 4.13±2.47 | 3.61±2.31 | −0.52 (−1.02 to −0.02) |
| Difference between groups (95% CI; p value) | −1.06 (−1.78 to −0.35) p=0.005 | |||||
| % Change in polyp no. | 9.7 (−2.6 to 22.0) | −12.4 (−24.7 to −0.6) | ||||
| Difference between groups† (95% CI; p value) | −22.4 (−39.6 to −5.1) p=0.012 | |||||
| % Change in polyp diameter* | 17.2 (−1.7 to 36.2) | −12.6 (−30.6 to 5.5) | ||||
| Difference between groups† (95% CI; p value) | −29.8 (−56.1 to −3.6) p=0.027 | |||||
| Change in global rectal polyp burden‡ | −0.34 (−0.56 to −0.11) | 0.09 (−0.14 to 0.32) | ||||
| Difference between groups (95% CI; p value) | 0.42 (0.10 to 0.75) p=0.011 | |||||
↵* Evaluable subjects were 22 (placebo) and 23 (EPA-FFA) for polyp number; and 19 (placebo) and 21 (EPA-FFA) for polyp diameter.
↵† A negative difference between treatment groups indicates a decrease in the EPA-FFA group compared with the placebo group.
↵‡ A negative value implies an increased global polyp burden. A positive value implies a decreased global polyp burden. Evaluable subjects were 25 in each of the placebo and EPA-FFA groups.
BL, baseline, EPA-FFA, eicosapentaenoic acid as the free fatty acid.